According to filings with the U.S. Securities and Exchange Commission, Pharmazz is raising $5,450,000.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Anil Gulati played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Pharmazz
Pharmazz, Inc. is an innovative biopharmaceutical company with an approved product, promising drug pipeline and a seasoned management team. It is a Delaware Corporation based in Willowbrook, Illinois, USA focused on discovering, acquiring, developing, and commercializing therapeutics that target critical care medicine. Pharmazz India Private Limited a majority owned subsidiary of Pharmazz, Inc. obtained marketing authorization of Lyfaquin (INN: Centhaquine) in India. Pharmazz has licensed exclusive worldwide rights to several molecules indicated for critically ill patients from Midwestern University, Downers Grove, USA. The company has a strong patent position and robust pipeline in different stages of clinical development.

To learn more about Pharmazz, visit http://pharmazz.com/

Contact:
Anil Gulati, President and Chief Executive Officer
630-780-6087
https://www.linkedin.com/in/anil-gulati-86765822/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.